A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Recruiting

Plain-English translation of NCT06863272 on ClinicalTrials.gov ↗ · Source last updated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

Trial locations(80 sites)

United States

UCLA Hematology & Oncology ( Site 0003), Los Angeles, California

University of California-Irvine Medical Center ( Site 0016), Orange, California

UCSF Medical Center at Mission Bay ( Site 0034), San Francisco, California

MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026), Washington D.C., District of Columbia

Memorial Sloan Kettering Cancer Center ( Site 0006), New York, New York